Tivic Health Validates European Patents In Great Britain, Germany, And France; European Patent EP3615133, Both Titled "Adaptive Trigger For a Microcurrent Stimulation Device"; European Patent EP3615134 Entitled "Sinus Treatment Device With Adaptive Circuit"

Patents cover methods used to identify key treatment points and dynamically personalize simulation

Tivic Health® Systems, Inc. (NASDAQ:TIVC), a health tech company developing and commercializing bioelectronic medicinal devices, announced today that it has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France. The Company believes these validations are an important step toward securing the foundation for an international market position.

Newly validated patents in Great Britain, Germany and France:

• European Patent EP3615133, both titled "Adaptive Trigger For a Microcurrent Stimulation Device" protects device and methods that the company uses to identify preferred treatment points and trigger the treatment mode of its sinus treatment device. Triggers can be programmed in various ways to improve consumer performance and ease of use.
• European Patent EP3615134 entitled "Sinus Treatment Device With Adaptive Circuit" protects the device and methods that the company uses to dynamically adjust stimulation voltage that is applied during a treatment phase, allowing for dynamic personalization of treatment. The dynamic changes in stimulation voltage help to maximize comfort, enhance device performance, and enrich user experience.